A player in the healthcare industry

LFB is a major industrial healthcare player in France. Its plasma-derived medicinal products are produced in two complementary bioproduction sites, in Les Ulis and Lille. A new plant under construction in Arras will triple LFB’s production capacity and thus accelerate its development globally. Two other sites specialise in the production of recombinant medicinal products, in Alès, France and in Massachusetts, United States.

Three industrial sites located in France

Les Ulis plant (Essonne) specialises in the upstream processing of plasma-derived medicinal products, from plasma reception to intermediate product.

The Lille plant (Nord) specialises in the downstream processing of plasma derived medicinal products, from intermediates to aseptic filling. Packaging
for LFB’s liquid products is carried out at Carvin (Pas-de-Calais).

The Alès plant develops cell lines and industrial-scale processes, and manufactures clinical and commercial batches of recombinant proteins,
including monoclonal antibodies, via its EMABling® technological platform. The Ales plant’s status as a CDMO (Contract Development & Manufacturing Organisation) means that it can offer production services
to third parties.


Major, sustained industrial investment in France

In Les Ulis and Lille, 80 million euros we invested in our industrial facilities between 2019 and 2021.

Investment in the new plant in Arras (France) has been implemented and  will enable LFB to step up its production capacity, supporting its international growth and increasing medicines available to patients.

See also

How are plasma derivatives produced?


How are plasma derivatives produced?

How are recombinant medicinal products produced by cell culture?


How are recombinant medicinal products produced by cell culture?